For research use only. Not for therapeutic Use.
Ketazolam（Cat No.:I007493）is a benzodiazepine medication used primarily for its anxiolytic, sedative, and muscle relaxant properties. It works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptors in the brain, leading to a calming effect on the central nervous system. Ketazolam is typically prescribed to treat anxiety disorders, stress-related conditions, and muscle tension. It has a moderate sedative effect compared to other benzodiazepines and is generally well tolerated. However, as with other benzodiazepines, prolonged use may lead to dependence, tolerance, and withdrawal symptoms.
| Catalog Number | I007493 |
| CAS Number | 27223-35-4 |
| Synonyms | Ketazolam, Anseren, Ansieten, Ansietil, Marcen, Sedatival, Sedotime, Solatran, Unakalm;11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione |
| Molecular Formula | C20H17ClN2O3 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | -20°C |
| IUPAC Name | 11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione |
| InChI | InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3 |
| InChIKey | PWAJCNITSBZRBL-UHFFFAOYSA-N |
| SMILES | CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C |
| Reference | </br>1:Ketazolam. Vega D, Fernández D, Echeverría G.Acta Crystallogr C. 2001 Jul;57(Pt 7):848-50. Epub 2001 Jul 9. PMID: 11443263 </br>2:Treatment of anxiety with ketazolam in elderly patients. Bresolin N, Monza G, Scarpini E, Scarlato G, Straneo G, Martinazzoli A, Benincà G, Cattoni C, De Candia R, Belloni G, et al.Clin Ther. 1988;10(5):536-42. PMID: 2908803 </br>3:Low doses of ketazolam in anxiety: a double-blind, placebo-controlled study. Scarpini E, Baron PG, Bet L, Bottini G, Bresolin N, Meola G, Pezzoli G, Vallar G, Monza GC, Scarlato G.Neuropsychobiology. 1988;20(2):74-7. PMID: 2908133 </br>4:Ketazolam once daily for spasticity: double-blind cross-over study. Basmajian JV, Shankardass K, Russell D.Arch Phys Med Rehabil. 1986 Aug;67(8):556-7. PMID: 2874780 </br>5:[Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Blaschke G, Kley H, Müller WE.Arzneimittelforschung. 1986 Jun;36(6):893-4. German. PMID: 2874815 </br>6:Pilot investigation of the quantitative EEG and clinical effects of ketazolam and the novel antiemetic nonabine in normal subjects. McClelland GR, Sutton JA.Psychopharmacology (Berl). 1985;85(3):306-8. PMID: 2860687 </br>7:Ketazolam treatment for spasticity: double-blind study of a new drug. Basmajian JV, Shankardass K, Russell D, Yucel V.Arch Phys Med Rehabil. 1984 Nov;65(11):698-701. PMID: 6149738 </br>8:A small double-blind comparison of ketazolam and diazepam in the treatment of anxiety by general practitioners in Great Britain. Davies JG, Rose AJ.Br J Clin Pract. 1983 Apr;37(4):136-9. No abstract available. PMID: 6136293 </br>9:[Screening and detection of ketazolam and oxazolam]. Schütz H, Fitz H, Suphachearabhan S.Arzneimittelforschung. 1983;33(4):507-12. German. No abstract available. PMID: 6683527 </br>10:Further assessment of benzodiazepine-tricyclic antidepressant interaction. Effectiveness of combined treatment with ketazolam-nortriptyline on conflict behaviour in rats. Cannizzaro G, Brucato AF, Provenzano PM.Arzneimittelforschung. 1982;32(9):1111-3. PMID: 6128985 |
